Thursday, November 12, 2026

2-Year Treasury Spike to 16-Month High Triggers FANG+ Selloff as AI Multiples Compress

The US 2-Year Treasury yield hit a 16-month high on June 5, triggering a coordinated selloff across Meta, Microsoft, Alphabet, NVIDIA, and Broadcom. Rising short rates are compressing terminal value assumptions for AI platform companies. A further 25–50 basis point move could accelerate rotation out of high-multiple AI names.

LM Salvado

June 9, 2026

2-Year Treasury Spike to 16-Month High Triggers FANG+ Selloff as AI Multiples Compress
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

The US 2-Year Treasury yield reached a 16-month high on June 5, landing simultaneously with a coordinated selloff across Meta, Microsoft, Alphabet, NVIDIA, and Broadcom.1 The timing was precise. Duration-sensitive growth stocks repriced as the short end of the yield curve rose.

AI platform companies carry high price-to-earnings multiples built on long-horizon earnings assumptions. When short rates rise, those distant cash flows discount more aggressively. The result: terminal value shrinks, and multiples compress even without any change in underlying business performance.

The FANG+ basket—the dominant index for mega-cap tech exposure—absorbed the shock collectively.1 Meta, Microsoft, Alphabet, NVIDIA, and Broadcom all moved lower in the same session. This was not stock-specific news. It was a rates-driven deration event.

The mechanism is straightforward. A 25–50 basis point further rise in 2-Year yields would tighten the discount rate applied to AI companies' projected revenues three to five years out.1 At current multiples, that math is punishing. Investors running duration-adjusted models are already reducing exposure.

Value and income sectors stand to benefit from continued rotation. Financials, energy, and dividend-paying industrials carry shorter-duration earnings profiles. When rates rise, relative attractiveness shifts toward those sectors and away from growth names priced on 2028–2030 AI monetization curves.

The compression hits hardest at companies where AI revenue remains projected rather than realized. NVIDIA is an exception—its data center sales are current and large—but its multiple still reflects future platform dominance. Any rate-driven multiple reset affects all five names, regardless of near-term earnings delivery.

Markets are now watching whether the 2-Year yield stabilizes or continues climbing. If it holds at current levels, the selloff may be a temporary recalibration. If yields push another 25–50 basis points higher, a sustained rotation out of AI platform stocks becomes the base case.1

For investors, the signal is structural: AI platform valuations are rate-sensitive in ways that were masked during the low-rate era. That sensitivity is now visible again.

In this story

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com